Bayer Schering Pharma AG Patent applications |
Patent application number | Title | Published |
20130060039 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. | 03-07-2013 |
20120258964 | 2-HETEROARYL CARBOXAMIDES - The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. | 10-11-2012 |
20120202842 | 2-HETEROARYLCARBOXYLIC ACID AMIDES - The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. | 08-09-2012 |
20110263591 | 2-HETEROARYL CARBOXAMIDES - The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. | 10-27-2011 |
20110217693 | Generation of Replication Competent Viruses for Therapeutic Use - The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease. | 09-08-2011 |
20110152266 | CO-CRYSTAL COMPOUND OF RIVAROXABAN AND MALONIC ACID - The present invention relates to a novel cocrystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid, to processes for its preparation, to medicaments comprising this compound and to their use for controlling diseases. | 06-23-2011 |
20110099789 | CATHETER BALLOON DRUG ADHERENCE TECHNIQUES AND METHODS - Various methods for optimizing coating of medical devices, such as balloon catheters are disclosed. One method configures catheter balloon folds based on balloon diameter and volume. Other methods include using a specifically-sized protective sheath, using a vacuum, using pressure, pulling the balloon through a coating solution, using at least one spacer or a wick between at least one fold for metering a therapeutic coating into the folds of the balloon, placing an intermediate layer between the balloon and the therapeutic coating, placing a soluble film having a therapeutic agent around the catheter balloon or inside the folds, and any combination thereof. Balloon catheters and catheter balloons having a specific folding configuration, a specifically-sized protective sheath, an intermediate layer, or a soluble film are also disclosed. | 05-05-2011 |
20110086013 | ACYLGLYCEROL ACETYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds. | 04-14-2011 |
20110008409 | PHARMACEUTICAL PREPARATION CONTAINING A GESTAGEN, AND KIT AND METHOD FOR TREATING ENDOMETRIOSIS USING THE PREPARATION - The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily dose units are administered in a method of prophylaxis and/or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated. | 01-13-2011 |
20100324085 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. | 12-23-2010 |
20100292184 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE - The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO | 11-18-2010 |
20100290991 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION - What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use. | 11-18-2010 |
20100222378 | 2-HETEROARYLCARBOXYLIC ACID AMIDES - The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. | 09-02-2010 |
20100144728 | Oxazolidinone For The Treatment And Prophylaxis Of Pulmonary Hypertension - The present invention relates to the use of factor Xa inhibitors, especially of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of pulmonary hypertension, and to the use thereof for the manufacture of medicaments for the treatment and/or prophylaxis of pulmonary hypertension. | 06-10-2010 |
20100137274 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION - The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) | 06-03-2010 |
20100136658 | GENERATION OF ONCOLYTIC ADENOVIRUSES AND USES THEREOF - The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided. | 06-03-2010 |
20100069615 | Regulation of Human Transmembrane Serine Protease - Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections. | 03-18-2010 |
20100056585 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzam- ide (MS-275) Polymorph B - The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I | 03-04-2010 |
20100029598 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor - The present invention relates to extended benzamide derivatives of the general formula I, to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP | 02-04-2010 |
20090280122 | USE OF A VIRUS REGIMEN FOR THE TREATMENT OF DISEASES - The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is described. The virus regimen is applied after reducing, shutting down or modifying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the virotherapy regimen. | 11-12-2009 |
20090240142 | SYSTEMS AND METHOD OF DELIVERING FLUIDS TO A PATIENT OF VARYING CONCENTRATION - A method for injection of an imaging contrast into a patient, includes: a. in a first phase, injecting a fluid having a first concentration of contrast agent for a first period of time; and b. in a second phase, injecting a fluid having a second concentration of contrast agent for a second period of time. The osmolarity of the second phase is higher than the osmolarity of the first phase. In several embodiments in which the contrast agent of the first phase is of the same composition as the contrast agent of the second phase, the second concentration can be higher than the first concentration. The first phase can, for example, precede the second phase. The method can further include: c. in a third phase, subsequent to the second phase, injecting a fluid having a third concentration of contrast agent for a third period of time. The osmolarity of the third phase is lower than the osmolarity of the second phase. In embodiments in which the composition of the contrast agent of the third phase is the same as the composition of the contrast agent of the second phase, the third concentration can be lower than the second concentration. The fluid injected in the first phase can, for example, be closer to the osmolarity of blood that the fluid injected in the second phase and can even be generally iso-osmolar to blood plasma (for example, within 20% or even 10% or less of the osmolarity of blood plasma of the patient). Likewise, the fluid injected in the third phase can be closer to the osmolarity of blood plasma that the fluid injected in the second phase and can even be generally iso-osmolar to blood. | 09-24-2009 |
20090208495 | ANTI-TUMOR EFFECTIVE PARAMYXOVIRUS - Paramyxovirus from the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueravirus and Fer-de-Lance virus are described, which can be used for the production of a medicament for the treatment of tumors. The virus has a selectivity to kill human tumor cells but not human normal differentiated and human normal proliferating cells at the same dose. By genetic engineering the virus can be modified in such a way that one or more genes are added or are replaced by the homologous genes of a related paramyxovirus. By that method the anti-tumor activity of the resulting chimeric virus is enhanced compared to the parental virus. | 08-20-2009 |
20090203715 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS - The present invention relates to 2-hetarylthiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof | 08-13-2009 |